PMID- 29065833
OWN - NLM
STAT- MEDLINE
DCOM- 20180807
LR  - 20180807
IS  - 1875-5704 (Electronic)
IS  - 1567-2018 (Linking)
VI  - 15
IP  - 1
DP  - 2018
TI  - On the Importance of Polyurethane and Polyurea Nanosystems for Future Drug 
      Delivery.
PG  - 37-43
LID - 10.2174/1567201814666171019102537 [doi]
AB  - BACKGROUND: During the last decade, polyurethanes and polyureas have emerged as 
      promising alternatives to classical polyacrylate-, polyester- and 
      polyaminoacid-based drug delivery nanosystems. They are not only biocompatible 
      and biodegradable, but also facilitate the manufacture of polymeric 
      nanostructured nanoparticles in quantitative yields. The versatile chemistry 
      reduces the amount of organic solvents used and allows the straightforward 
      multifunctionalization of polymer precursors with the desired targeting molecule 
      at each stage of the process. OBJECTIVES: To highlight the common issues 
      encountered in current drug delivery systems (DDSs) and the state of the art of 
      polyurethane and polyurea polymers that self-assemble in a stratified manner by 
      hydrophobic interactions. Finally, we discuss the importance of taking a holistic 
      view when applying polymer nanotechnologies, in order to enhance their efficiency 
      during preclinical and clinical studies. CONCLUSIONS: Polyurethane-polyurea 
      nanoparticles (PUUa NPs) emerge as suitable platforms to be manufactured in a 
      cost-effective manner at industrial scale and following environmentally friendly 
      synthetic methods. Furthermore, they allow the controlled delivery of a wide 
      range of drugs and can be rapidly adapted to many clinical requirements by means 
      of FDA-approved precursors. Additionally, the ease with which PUUa nanoparticles 
      are biodegraded ensures control over temporal aspects of drug delivery compared 
      to other nanosystems. These advantages make PUUa NPs attractive drug delivery 
      vehicles as long as adequate safety and ethical guidelines for new NP 
      formulations are developed.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Rocas, Pau
AU  - Rocas P
AD  - Nanobiotechnological Polymers Division, Ecopol Tech S.L., Industria 7, El Foix 
      Business Park, 43720 L'Arboc. Spain.
FAU - Cusco, Cristina
AU  - Cusco C
AD  - Nanobiotechnological Polymers Division, Ecopol Tech S.L., Industria 7, El Foix 
      Business Park, 43720 L'Arboc. Spain.
FAU - Rocas, Josep
AU  - Rocas J
AD  - Nanobiotechnological Polymers Division, Ecopol Tech S.L., Industria 7, El Foix 
      Business Park, 43720 L'Arboc. Spain.
FAU - Albericio, Fernando
AU  - Albericio F
AD  - School of Chemistry & Physics, University of Kwazulu-Natal, 4041 Durban. South 
      Africa.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Deliv
JT  - Current drug delivery
JID - 101208455
RN  - 0 (Polymers)
RN  - 0 (Polyurethanes)
RN  - 37955-36-5 (polyurea)
SB  - IM
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Nanoparticles/*chemistry
MH  - *Nanotechnology
MH  - Polymers/*chemistry
MH  - Polyurethanes/*chemistry
OTO - NOTNLM
OT  - Drug discovery
OT  - delivery systems
OT  - encapsulation
OT  - medicinal chemistry
OT  - polymers
OT  - targeting
EDAT- 2017/10/27 06:00
MHDA- 2018/08/08 06:00
CRDT- 2017/10/26 06:00
PHST- 2017/09/07 00:00 [received]
PHST- 2017/10/17 00:00 [revised]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2018/08/08 06:00 [medline]
PHST- 2017/10/26 06:00 [entrez]
AID - CDD-EPUB-86430 [pii]
AID - 10.2174/1567201814666171019102537 [doi]
PST - ppublish
SO  - Curr Drug Deliv. 2018;15(1):37-43. doi: 10.2174/1567201814666171019102537.